Indian pharma's twin woes

The Indian pharmaceutical industry is beset by two adverse conditions - one is a recent development and the other a long-standing malady. Most recently, leading pharmaceutical company Ranbaxy met with yet another regulatory mishap: the United States Food and Drug Administration, or FDA, withdrew approval for the firm's Toansa plant because of significant lapses in manufacturing practices.

Read Full Story>>